Previously recorded as Respicardia, Inc. (to 2021)
32 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Nov 2027
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2029 · High confidence
Also notable
Ends Oct 2031 · High confidence
Also notable
Ends Oct 2030 · High confidence
Also notable
Ends Jan 2028 · High confidence
Also notable
Ends Jul 2029 · High confidence
Also notable
Ends Jun 2031 · High confidence
Also notable
Ends May 2029 · High confidence
Also notable
Ends Dec 2028 · High confidence
Transvenous Phrenic Nerve Stimulation System
US 10,406,366
Cited by 146 later US patents, top 1% of utility patents granted in 2019 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Respiratory Rectification
US 8,233,987
Cited by 137 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Medical Lead with Preformed Bias
US 9,468,755
Cited by 92 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders
US 8,909,341
Cited by 104 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Muscle and Nerve Stimulation
US 8,433,412
Cited by 110 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Medical Lead and Implantation
US 9,744,349
Cited by 55 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Detecting and Treating Disordered Breathing
US 11,305,114
Cited by 10 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2029.
Transvascular Medical Lead
US 9,199,075
Cited by 39 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2028.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders (US 10,300,270) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Mar 10, 2027The maintenance fee for Transvenous Phrenic Nerve Stimulation System (US 10,406,366) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
- 2 fees due Jun 1 to 17, 2027 · next Jun 1
- 2 fees due Jul 9 to 28, 2027 · next Jul 9
- 2 fees due Sep 29 to 30, 2027 · next Sep 29
Recent changes
- Oct 28Assignment recorded on 1 record: Zoll Respicardia, Inc. to Zoll Medical Corporation Recorded Oct 28, 2026, executed Oct 26, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76537, frame 300.
- 1 term has ended since Aug 23, 2026
- Nov 17 US 10,518,090 System and Method to Modulate Phrenic Nerve to Prevent Sleep Apnea · term ended
What they patent
The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Medical Lead with Preformed Bias | 5 in force | to Oct 2030 |
| System and Method to Modulate Phrenic Nerve to Prevent Sleep Apnea | 5 in force | to Jan 2030 |
| Transvascular Medical Lead | 5 in force | to Dec 2028 |
| Detecting and Treating Disordered Breathing | 4 in force | to Jan 2032 |
| Respiratory Rectification | 4 in force | to Oct 2031 |
| Medical Lead and Implantation | 3 in force | to Sep 2033 |
| Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders | 3 in force | to Jan 2028 |
| Muscle and Nerve Stimulation | 2 in force | to Jul 2029 |
| Monitoring System and User Interface for Monitoring Implantable Disordered Breathing Treatment Systems | 1 in force | to Apr 2044 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,305,119 | System and Method to Modulate Phrenic Nerve to Prevent Sleep Apnea In force · High confidence | In force | High confidence | |
| US 8,909,341 | Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders In force · High confidence | In force | High confidence | |
| US 9,744,351 | Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders In force · Medium confidence | In force | Medium confidence | |
| US 10,300,270 | Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders In force · Medium confidence | In force | Medium confidence | |
| US 12,616,839 | System and Method to Modulate Phrenic Nerve to Prevent Sleep Apnea In force · Medium confidence | In force | Medium confidence | |
| US 12,179,014 | Transvenous Phrenic Nerve Stimulation System In force · High confidence | In force | High confidence | |
| US 12,558,539 | Detecting and Treating Disordered Breathing In force · Medium confidence | In force | Medium confidence | |
| US 9,199,075 | Transvascular Medical Lead In force · High confidence | In force | High confidence | |
| US 10,543,363 | Transvascular Medical Lead In force · High confidence | In force | High confidence | |
| US 11,389,648 | Transvascular Medical Lead In force · High confidence | In force | High confidence |
Also on record, not counted in the 32: 1 patent in force now held by others · 1 patent ended · 11 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.